Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders

Molecular Pharmacology

Volumn 80, Issue 3, 2011, Pages 466-475

  Yamamoto, Naoko ^a   Honma, Masashi ^a   Suzuki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; ERLOTINIB; GEFITINIB; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CELL SECRETION; CONTROLLED STUDY; HYPERSENSITIVITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN DISEASE;

BASE SEQUENCE; CELL LINE; CHROMATOGRAPHY, LIQUID; HUMANS; JURKAT CELLS; LYMPHOCYTES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RNA, SMALL INTERFERING; SKIN DISEASES; TANDEM MASS SPECTROMETRY;

EID: 80051974226     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.070862     Document Type: Article

References (49)

1. Albanell J., Rojo F., Averbuch S., Feyereislova A., Mascaro J.M., Herbst R., LoRusso P., Rischin D., Sauleda S., Gee J., et al. (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124. (Pubitemid 34032602)
2. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi DR, and Cohen P. (2007) The selectivity of protein kinase inhibitors: A further update. Biochem J 408:297-315.
3. Belkina N.V., Liu Y., Hao J.J., Karasuyama H, and Shaw S. (2009) LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation. Proc Natl Acad Sci USA 106:4707-4712.
4. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578. (Pubitemid 43209104)
5. Burakov A.V., Zhapparova O.N., Kovalenko O.V., Zinovkina L.A., Potekhina E.S., Shanina N.A., Weiss D.G., Kuznetsov SA, and Nadezhdina E.S. (2008) Ste20-related protein kinase LOSK (SLK) controls microtubule radial array in interphase. Mol Biol Cell 19:1952-1961.
6. Busam K.J., Capodieci P., Motzer R., Kiehn T., Phelan D, and Halpern A.C. (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169-1176. (Pubitemid 34204207)
7. Chatila T., Silverman L., Miller R, and Geha R. (1989) Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol 143:1283-1289. (Pubitemid 19211362)
8. Chu D.H., Morita CT, and Weiss A. (1998) The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol Rev 165:167-180. (Pubitemid 28524211)
9. Clevers H., Alarcon B., Wileman T, and Terhorst C. (1988) The T cell receptor/CD3 complex: A dynamic protein ensemble. Annu Rev Immunol 6:629-662. (Pubitemid 19141599)
10. Deane JA and Hickey M.J. (2009) Molecular mechanisms of leukocyte trafficking in T-cell-mediated skin inflammation: insights from intravital imaging. Expert Rev Mol Med 11:e25.
11. Deininger M., Buchdunger E, and Druker B.J. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653. (Pubitemid 40446252)
12. Franklin R.A., Tordai A., Patel H., Gardner A.M., Johnson GL, and Gelfand E.W. (1994) Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. J Clin Invest 93:2134-2140. (Pubitemid 24143095)
13. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., Rischin D., et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [published erratum appears in J Clin Oncol 22:4811, 2004]. J Clin Oncol 21:2237-2246. (Pubitemid 46621858)
14. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743. (Pubitemid 46021510)
15. Guttman-Yassky E., Mita A., De Jonge M., Matthews L., McCarthy S., Iwata K.K., Verweij J., Rowinsky EK, and Krueger J.G. (2010) Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 46:2010-2019.
16. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., Eckhardt S.G., Tolcher A., Britten C.D., Denis L., et al. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279. (Pubitemid 32591445)
17. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132.
18. Kari C., Chan T.O., Rocha de Quadros M, and Rodeck U. (2003) Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Res 63:1-5. (Pubitemid 36070409)
19. Kerkela R., Woulfe K.C., Durand J.B., Vagnozzi R., Kramer D., Chu T.F., Beahm C., Chen MH, and Force T. (2009) Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2:15-25.
20. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J. Jr, Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158. (Pubitemid 37432975)
21. Lacouture M.E. (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803-812.
22. Lenschow D.J., Walunas TL, and Bluestone J.A. (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233-258. (Pubitemid 26130184)
23. Li J., Karlsson M.O., Brahmer J., Spitz A., Zhao M., Hidalgo M, and Baker S.D. (2006) CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 98:1714-1723. (Pubitemid 44942709)
24. Li J., Zhao M., He P., Hidalgo M, and Baker S.D. (2007) Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13:3731-3737. (Pubitemid 46955138)
25. Marchetti S., De Vries N.A., Buckle T., Bolijn M.J., Van Eijndhoven M.A., Beijnen J.H., Mazzanti R., Van Tellingen O, and Schellens J.H. (2008) Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 7:2280-2287.
26. Mascia F., Mariani V., Girolomoni G, and Pastore S. (2003) Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163:303-312. (Pubitemid 36759615)
27. McKillop D., McCormick A.D., Millar A., Miles G.S., Phillips PJ, and HutchisonM.(2005) Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 35:39-50. (Pubitemid 40459216)
28. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M.J., Moyer M.P., et al. (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848. (Pubitemid 27468992)
29. Nakagawa K., Tamura T., Negoro S., Kudoh S., Yamamoto N., Yamamoto N., Takeda K., Swaisland H., Nakatani I., Hirose M., et al. (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14:922-930. (Pubitemid 36827209)
30. Pallis A.G., Mavroudis D., Androulakis N., Souglakos J., Kouroussis C., Bozionelou V., Vlachonikolis IG, and Georgoulias V. (2003) ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer 40:301-307. (Pubitemid 36627710)
31. Rakhit A., Pantze M.P., Fettner S., Jones H.M., Charoin J.E., Riek M., Lum BL, and Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: Computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 64:31-41.
32. Roovers K., Wagner S., Storbeck C.J., O'Reilly P., Lo V., Northey J.J., Chmielecki J., Muller W.J., Siegel PM, and Sabourin L.A. (2009) The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility. Oncogene 28:2839-2848.
33. Rudin C.M., Liu W., Desai A., Karrison T., Jiang X., Janisch L., Das S., Ramirez J., Poonkuzhali B., Schuetz E., et al. (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119-1127.
34. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B.R., Murray D.M., Knight W.B., Mullin R.J., et al. (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85-94.
35. Segaert S and Van Cutsem E. (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425-1433. (Pubitemid 41222414)
36. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132. (Pubitemid 41058344)
37. Sleijfer S and Wiemer E. (2008) Dose selection in phase I studies: Why we should always go for the top. J Clin Oncol 26:1576-1578.
38. Swaisland H.C., Ranson M., Smith R.P., Leadbetter J., Laight A., McKillop D, and Wild M.J. (2005) Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44:1067-1081. (Pubitemid 41356392)
39. Tao L., Wadsworth S., Mercer J., Mueller C., Lynn K., Siekierka J, and August A. (2002) Opposing roles of serine/threonine kinases MEKK1 and LOK in regulating the CD28 responsive element in T-cells. Biochem J 363:175-182. (Pubitemid 34280624)
40. Thomas F., Rochaix P., White-Koning M., Hennebelle I., Sarini J., Benlyazid A., Malard L., Lefebvre J.L., Chatelut E, and Delord J.P. (2009) Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 45:2316-2323.
41. Toi M., Iwata H., Fujiwara Y., Ito Y., Nakamura S., Tokuda Y., Taguchi T., Rai Y., Aogi K., Arai T., et al. (2009) Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101:1676-1682.
42. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., Canon J.L., Van Laethem J.L., Maurel J., Richardson G., et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664. (Pubitemid 46797944)
43. Vandyke K., Fitter S., Dewar A.L., Hughes TP, and Zannettino A.C. (2010) Dysregulation of bone remodeling by imatinib mesylate. Blood 115:766-774.
44. Walter S.A., Cutler R.E. Jr, Martinez R., Gishizky M, and Hill R.J. (2003) Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue. J Biol Chem 278:18221-18228. (Pubitemid 36799439)
45. Wang S., Guo P., Wang X., Zhou Q, and Gallo J.M. (2008) Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther 7:407-417. (Pubitemid 351302534)
46. Whitehurst CE and Geppert T.D. (1996) MEK1 and the extracellular signal-regulated kinases are required for the stimulation of IL-2 gene transcription in T cells. J Immunol 156:1020-1029. (Pubitemid 26048095)
47. Woodworth C.D., Michael E., Marker D., Allen S., Smith L, and Nees M. (2005) Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 4:650-658. (Pubitemid 40601847)
48. Yamada E., Tsujikawa K., Itoh S., Kameda Y., Kohama Y, and Yamamoto H. (2000) Molecular cloning and characterization of a novel human STE20-like kinase, hSLK. Biochim Biophys Acta 1495:250-262. (Pubitemid 30103546)
49. Yamamoto N., Horiike A., Fujisaka Y., Murakami H., Shimoyama T., Yamada Y, and Tamura T. (2008) Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 61:489-496. (Pubitemid 350275984)